The short answer
High-dose niacin can worsen glucose control, but an added safety interaction specifically with canagliflozin has not been established. The high-dose clinical evidence should not be applied to ordinary food-level vitamin B3.
What this answer covers
Pharmacologic oral nicotinic acid, especially extended-release preparations; nutritional doses and nicotinamide differ.
- Supplement or preparation
- Niacin
- Medication ingredient
- canagliflozin
High-dose niacin has clinical glucose effects
A large study of extended-release niacin plus laropiprant found more serious disturbances in diabetes control. It did not test canagliflozin as an exact combination.
Do not turn intrinsic effects into proven pair toxicity
The trial supports attention to glucose when pharmacologic niacin changes. It does not show that canagliflozin increases niacin toxicity or measure an added adverse-event rate for this pair.
Form and dose matter
The high-dose combination cannot establish the same risk from food-level vitamin B3 or every nicotinamide product. Laropiprant also limits attribution of all outcomes to niacin alone.
Review starts and stops
Discuss pharmacologic niacin changes with the diabetes team and review glucose readings. Do not adjust canagliflozin independently or rely on a short supplement-spacing interval.
Evidence and practical considerations
Side effects & toxicity
High-dose niacin-combination dysglycemia is not an exact canagliflozin safety interaction; narrower glucose-review rationale retained.
- Exact scope
- Pharmacologic oral nicotinic acid, especially extended-release preparations; nutritional doses and nicotinamide differ. with Oral canagliflozin RxCUI1373458 IN; agent-specific renal and metabolic mechanisms.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No arbitrary interval, class-only metabolism assumption or unmeasured pair-event rate.
Factors that may matter: Preparation; Dose; Kidney function; Volume status; Other diabetes treatment.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral canagliflozin
SGLT2 inhibition increases urinary glucose. Volume contraction can cause hypotension or acute kidney injury, with risk modifiers. UGT inducers may lower drug exposure and effectiveness. Insulin/secretagogue co-use increases hypoglycemia risk.
How this applies: Exact single-ingredient canagliflozin, not all SGLT2 agents or combination products.
Warnings do not establish every botanical interaction or routine sodium supplementation. Renal function and whole regimen matter.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 25,673high-vascular-risk adults.
High-dose niacin-laropiprant increased serious disturbances in diabetes control compared with placebo.
How this applies: Indirect for exact canagliflozin; source exposure and clinical endpoint retained.
High-dose niacin/laropiprant combination, not exact canagliflozin exposure or ordinary vitamin intake.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact canagliflozin article separating volume effects, metabolic exposure and intrinsic supplement risks. | |
| Research summary published |
Article revision: 9699852b605ba8cb
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.